Home » Resources » Blog » Engineering iPSC-derived Natural Killer Cells for Enhanced Efficacy of Cancer Therapies
Engineering iPSC-derived Natural Killer Cells for Enhanced Efficacy of Cancer Therapies
Friday, March 23, 2018 - 08:48
In this webinar, Professor Bruce Walcheck discusses current approaches to augment antibody-dependent cell-mediated cytotoxicity (ADCC) by Natural Killer (NK) cells as therapies to treat cancer. This webinar also includes exciting research from his lab focused on generating enhanced versions of CD16A, an Fc receptor expressed by NK cells that recognizes tumor-targeting mAbs. Finally, his discussion covers the genetic manipulation of induced pluripotent stem cells (iPSCs) to derive NK cells engineered to express modified CD16A, and their potential for improving the efficacy of tumor-targeting therapeutic mAbs.
Current approaches using NK cells as therapies to treat cancer
Augmenting ADCC using NK cells
Genetic manipulation of iPSCs to derive engineered NK cells
Generating enhanced versions of CD16A for tumor targeting